Diagnostic pathways, cardiac manifestations and outcomes in light chain amyloidosis: analysis of a US claims database
This claims database study suggests that patients with delayed diagnosis experienced more CV-related emergency room visits and inpatient hospitalisations, underscoring the need for timely diagnosis of AL amyloidosis and the role of cardiologists in the diagnostic pathway.
Authors
- Richa Manwani
- Jeffrey C. Thompson (ORCID: https://orcid.org/0000-0001-5734-0004)
- Isabelle Lousada (ORCID: https://orcid.org/0000-0002-3506-0359)
- Mathew S. Maurer (ORCID: https://orcid.org/0000-0001-5400-5008)
- Genevieve Lyons (ORCID: https://orcid.org/0000-0002-7936-6210)
- Julia Catini
Institutions
- Columbia University Irving Medical Center (US)
- Amyloidosis Foundation (US)
- Alexion Pharmaceuticals (United States) (US)
- Alexion Pharma (Switzerland) (CH)
Publication Details
- Journal
- Open Heart
- Published
- 2025-01-01
- DOI
- https://doi.org/10.1136/openhrt-2024-003124
- Primary Topic
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- AstraZeneca
- Alexion Pharmaceuticals